Baystreet Staff - Monday, October 27, 2014 Sarepta Therapeutics (SRPT) plummets on FDA requirements Sarepta Therapeutics (NASDAQ: SRPT) dropped 35.6% to $15.17 on the FDA requirement of additional data from Sarepta on Eteplirsen. Share volume was 3.3 million, compared to an all-day average of 1.2 million